循环肿瘤DNA预测高危II/III期黑色素瘤术后生存
研究纳入161例高危II/III期黑色素瘤术后患者,采用微滴数字PCR检测血浆BRAF/NRAS突变ctDNA。可检测到ctDNA者无病间期、无远处转移间期和总生存均显著更差,提示ctDNA可预测复发与生存并辅助辅助治疗选择。
要点
- 术后可检测到ctDNA的高危黑色素瘤患者复发和死亡风险显著升高。
- ctDNA检测或有助于筛选可从辅助治疗中获益的患者。
- 该结果来自AVAST-M辅助治疗试验的回顾性ctDNA分析。
核心结论
- 在高危已切除黑色素瘤患者中,术后可检测到ctDNA可预测复发和生存,并可能辅助辅助治疗的患者选择。
研究设计与样本
- 研究为AVAST-M辅助治疗试验中的回顾性分析,纳入161例高危II/III期黑色素瘤术后患者。
- 采用微滴数字PCR检测术后血浆中BRAF和NRAS突变以判断ctDNA。
主要发现
- 132例BRAF突变患者样本中15例(11%)检出突变ctDNA,29例NRAS突变患者样本中4例(14%)检出。
- 可检测到ctDNA者无病间期显著更短(HR 3.12;95%CI 1.79-5.47;P<0.0001),无远处转移间期也显著更短(HR 3.22;95%CI 1.80-5.79;P<0.0001)。
- 校正体能状态和疾病分期后,ctDNA仍显著预测无病间期(HR 3.26;95%CI 1.83-5.83;P<0.0001)和无远处转移间期(HR 3.45;95%CI 1.88-6.34;P<0.0001)。
- 可检测到ctDNA者5年总生存率为33%(95%CI 14%-55%),未检测到者为65%(95%CI 56%-72%)。
- 可检测到ctDNA者总生存显著更差(HR 2.63;95%CI 1.40-4.96;P=0.003),校正体能状态后仍显著(HR 2.50;95%CI 1.32-4.74;P=0.005)。
临床怎么用
- 对高危II/III期黑色素瘤术后患者,可考虑检测血浆BRAF/NRAS突变ctDNA以辅助评估复发和死亡风险。
- ctDNA结果可能帮助识别更可能从辅助治疗中获益的高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with high-risk stage II/III resected melanoma commonly develop distant metastases. At present, we cannot differentiate between patients who will recur or those who are cured by surgery. We investigated if circulating tumor DNA (ctDNA) can predict relapse and survival in patients with resected melanoma. PATIENTS AND METHODS: We carried out droplet digital polymerase chain reaction to detect BRAF and NRAS mutations in plasma taken after surgery from 161 stage II/III high-risk melanoma patients enrolled in the AVAST-M adjuvant trial. RESULTS: Mutant BRAF or NRAS ctDNA was detected (≥1 copy of mutant ctDNA) in 15/132 (11%) BRAF mutant patient samples and 4/29 (14%) NRAS mutant patient samples. Patients with detectable ctDNA had a decreased disease-free interval [DFI; hazard ratio (HR) 3.12; 95% confidence interval (CI) 1.79-5.47; P < 0.0001] and distant metastasis-free interval (DMFI; HR 3.22; 95% CI 1.80-5.79; P < 0.0001) versus those with undetectable ctDNA. Detectable ctDNA remained a significant predictor after adjustment for performance status and disease stage (DFI: HR 3.26, 95% CI 1.83-5.83, P < 0.0001; DMFI: HR 3.45, 95% CI 1.88-6.34, P < 0.0001). Five-year overall survival rate for patients with detectable ctDNA was 33% (95% CI 14%-55%) versus 65% (95% CI 56%-72%) for those with undetectable ctDNA. Overall survival was significantly worse for patients with detectable ctDNA (HR 2.63; 95% CI 1.40-4.96); P = 0.003) and remained significant after adjustment for performance status (HR 2.50, 95% CI 1.32-4.74, P = 0.005). CONCLUSION: ctDNA predicts for relapse and survival in high-risk resected melanoma and could aid selection of patients for adjuvant therapy. CLINICAL TRIAL NUMBER: ISRCTN 81261306.
引用
- Lee RJ, Gremel G, Marshall A, et al. Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma. Ann Oncol. 2018. PMID: 29112704. doi:10.1093/annonc/mdx717
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。